



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/561,829
				Filing Date	December 21, 2005
				First Named Inventor	Shaharyar Khan
				Group Art Unit	1633
Examiner Name	Qian Janice Li				
Sheet 1 of 2	Attorney Docket Number		GNC 0001		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		6,171,863		Weissig, et al.	01-09-2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ²	Kind Code ⁵ (if known)				

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/561,829
				Filing Date	December 21, 2005
				First Named Inventor	Shaharyar Khan
				Group Art Unit	1633
				Examiner Name	Qian Janice Li
Sheet	2	of	2	Attorney Docket Number	GNC 0001

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CAO, et al., "In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis," <i>J. Neuroscience</i> , 22(13): 5423-31 (2002).	
		DOLGILEVICH, et al., "Transduction of TAT fusion proteins into osteoclasts and osteoblasts," <i>Biochem. Biophys. Res. Commun.</i> , 299(3): 505-9 (2002).	
		EMBURY, et al., "Proteins linked to a protein transduction domain efficiently transduce pancreatic islets," <i>Diabetes</i> , 50(8): 1706-13 (2001).	
		FENTON, et al., "The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line," <i>J. Immunol. Methods</i> , 212(1): 41-8 (1998).	
		FORRER and JAUSSE, "High-level expression of soluble heterologous proteins in the cytoplasm of <i>Escherichia coli</i> by fusion to the bacteriophage Lambda head protein D," <i>Gene</i> , 224(1-2): 45-52 (1998).	
		LI, et al., "Transduction of human catalase mediated by a HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells," <i>Free Radical Biology & Medicine</i> , 31(11): 1509-19 (2001).	
		STERNBERG and HOESS, "Display of peptides and proteins on the surface of bacteriophage λ," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92(5): 1609-13 (1995).	
		TOBOREK, et al., "HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium," <i>J. Neurochem.</i> , 84(1): 169-79 (2003).	
		TSENG, et al., "Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study," <i>Mol. Pharmacology</i> , 62(4): 864-72 (2002).	
		VASQUEZ and JOHNSON, "Green fluorescent protein as a reporter of adenovirus-mediated gene transfer and expression in the hypothalamic-neurohypophyseal system," <i>Methods Mol. Biol.</i> , 183: 321-9 (2002).	
		VIVÈS, et al., "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272(25): 16010-7 (1997).	
		WHEELER, et al., "Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain," <i>Biochem. Biophys. Res. Commun.</i> , 301(1): 54-9 (2003).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+